6th European Congress on Cancer and Oncology Research
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to 6th European Congress on Cancer and Oncology Research — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds
About this event
6th European Congress on Cancer and Oncology Research
Dates: October 15–18, 2025
Venue: International Conference Centre Munich (ICM), Munich, Germany
Event type: Medical Research, Oncology, Cancer Treatment Advancements, Healthcare Innovation, Multidisciplinary Collaboration
Estimated attendance: 2,500+ global participants including researchers, clinicians, oncologists, healthcare professionals, and industry leaders.
Event Overview
The 6th European Congress on Cancer and Oncology Research stands as a premier platform for advancing global dialogue on cutting-edge cancer research, innovative treatment modalities, and interdisciplinary collaboration. This year’s edition will convene leading experts from academia, clinical practice, pharmaceuticals, and biotechnology to address critical challenges and breakthroughs in oncology. Key themes include precision medicine, immuno-oncology, radiology advancements, patient-centered care, and translational research bridging laboratory discoveries to clinical applications.
Who Attends
Target attendees include: Medical Oncologists, Surgical Oncologists, Radiation Oncologists, Researchers, Academics, Clinical Trial Coordinators, Pharmaceutical Executives, Biotech Innovators, Healthcare Policymakers, Nursing Professionals, Cancer Survivors Advocates, and Industry Partners. The event also attracts startups, investors, and regulatory bodies shaping the future of oncology.
Location & Geographic Reach
Hosted in Munich, Germany—a hub for biomedical innovation—the Congress draws a global audience with a strong European contingent. Attendees originate from over 70 countries, including major representation from the EU, North America, Asia-Pacific, and emerging markets in Africa and Latin America. Munich’s strategic location ensures accessibility for both European and international delegates.
Key Focus Areas & Buyer Engagement
Central themes include:
• Personalized cancer therapies and genomics
• AI-driven diagnostics and treatment planning
• Oncology nursing and supportive care
• Regulatory frameworks for drug approvals
• Collaborative clinical trials and data sharing
Buyer engagement opportunities span pharmaceutical partnerships, medical device exhibitions, research funding collaborations, and recruitment for clinical studies.
Industries Represented
Core industries include: Biotechnology, Pharmaceuticals, Medical Device Manufacturing, Healthcare Services, Academic Research Institutions, Government Health Agencies, Non-Profit Advocacy Groups, and Venture Capital Firms. Cross-sector participation from AI/tech companies and CROs (Clinical Research Organizations) is also anticipated.
Why Attend?
Delegates will gain insights into the latest scientific discoveries, network with decision-makers, and explore commercialization opportunities. The Congress emphasizes actionable strategies to improve patient outcomes, accelerate drug development, and foster global partnerships to combat cancer effectively.
Data sheet
6th European Congress on Cancer and Oncology Research – Event Attendee & Buyer Profile Analysis
Event date: 22 October 2026 – 23 October 2026
Location: Barcelona, Spain
Event status: Upcoming
Research date: 30 June 2026
Event Overview
| Event Name | 6th European Congress on Cancer and Oncology Research |
| Event Date | 22 October 2026 – 23 October 2026 |
| Event Status | Upcoming |
| Venue | Barcelona venue not separately verified in the materials provided; city-level venue information supplied as Barcelona. |
| City | Barcelona |
| State / Region | Catalonia |
| Country | Spain |
| Organizer | Organizer not publicly confirmed in the materials provided for the 2026 Barcelona edition. |
| Official Event Website | Official current-year website link not supplied in the materials provided. |
| Event Type | Scientific congress / medical research conference / oncology and cancer care innovation event |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research |
| Audience Reach | Likely international / pan-European based on the congress positioning and prior reference description. |
| Estimated Attendance / Expected Footfall | Attendance figure not publicly confirmed by the organizer for the 2026 edition. Historical reference supplied by the user indicates 2,500+ global participants for the 2025 edition. |
| Attendance Data Reliability | Historical / prior-year evidence provided by the user; current-year attendance not confirmed. |
| Main Purpose of Event | To convene oncology researchers, clinicians, healthcare leaders, biotech and pharmaceutical stakeholders, and related industry participants to exchange research findings, clinical insights, treatment advances, and partnership opportunities across cancer care. |
About the Event
The 6th European Congress on Cancer and Oncology Research is positioned as a specialist medical and scientific congress focused on cancer research, treatment advances, translational medicine, and multidisciplinary collaboration. Based on the event description supplied, the congress brings together oncologists, researchers, clinicians, pharmaceutical and biotechnology stakeholders, healthcare professionals, and policy or advocacy participants interested in improving cancer diagnosis, treatment, and patient outcomes.
From a commercial and business-development perspective, this type of congress is relevant less as a high-volume trade fair and more as a high-value relationship environment for clinical partnerships, scientific collaboration, medical technology evaluation, trial support services, data and digital health solutions, laboratory platforms, pharmaceutical development, and hospital or cancer-center engagement. Buyer influence is typically strongest among clinical decision-makers, research leaders, hospital administrators, translational medicine teams, and life sciences business development executives.
1. Who Attends: Buyers / Attendees
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Medical oncologists and cancer specialists | Hospitals, cancer centers, university clinics | Strong clinical influence over treatment pathways, technology evaluation, and adoption decisions | Highly relevant for therapeutics, diagnostics, imaging, digital health, and decision-support vendors |
| Researchers and principal investigators | Academic institutes, translational research centers, laboratories | Influence protocol design, platform selection, trial partnerships, and grant-backed procurement | High relevance for lab tools, data platforms, CRO services, sequencing, biomarker, and AI analytics providers |
| Hospital procurement and category teams | Public and private hospital systems | Direct procurement authority for devices, consumables, IT, and contracted services | Relevant for vendors seeking institutional purchasing routes and framework contracts |
| Clinical trial coordinators and study operations teams | Academic medical centers, CROs, sponsor organizations | Operational influence on trial systems, patient recruitment tools, biosample logistics, and data capture | Relevant for EDC, eClinical, patient engagement, logistics, and site-support providers |
| Pharmaceutical business and medical affairs leaders | Oncology-focused pharmaceutical companies | Budget influence for partnerships, sponsorship, pipeline collaboration, and medical education programs | Strong relevance for CROs, biomarker vendors, market access support, and scientific communications suppliers |
| Biotechnology founders and R&D leaders | Biotech startups, scale-ups, translational medicine companies | Influence external development, discovery tools, assays, and trial partnerships | Relevant for scientific instrumentation, software, outsourced research, and partnership outreach |
| Healthcare policymakers and public health stakeholders | Health ministries, cancer networks, public agencies, reimbursement bodies | Indirect influence on policy, reimbursement, screening adoption, and institutional priorities | Useful for long-cycle policy engagement, public sector positioning, and ecosystem partnerships |
| Nursing leaders and patient care teams | Hospitals, infusion centers, oncology departments | Operational influence on workflow, care pathways, patient experience, and supportive care tools | Relevant for care-delivery software, patient engagement, infusion support, and pathway optimization |
| Investors and strategic partners | Life sciences investors, venture groups, strategic innovation teams | Influence funding, licensing, and commercial partnerships | Relevant for companies seeking capital, licensing, and strategic collaboration discussions |
2. Event Location and Attendee Geographic Origin
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Host city: Barcelona | Local clinicians, researchers, hospital networks, universities, life sciences companies | High | Barcelona is a major biomedical and healthcare innovation hub, supporting strong local professional attendance potential. |
| Host region: Catalonia | Regional hospital systems, cancer institutes, biotech and academic attendees | High | Likely regional feeder market for care providers, translational research centers, and public health stakeholders. |
| Spain | National oncology professionals, university hospitals, pharmaceutical affiliates, medical societies | High | Likely national draw due to disease-area relevance and Barcelona accessibility. |
| Wider Europe | European researchers, cancer centers, biotech firms, pharma regional teams | High | Likely core audience based on the “European Congress” positioning. |
| International markets | Global participants from academia, pharma, biotech, and healthcare innovation sectors | Medium to High | Historical description supplied by the user referenced global participation, but current-year country mix is not confirmed. |
3. Audience Reach
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification with strong European concentration | The congress theme, disease-area specialization, and user-provided prior reference indicate international participation potential, while the title suggests a core pan-European audience base. |
4. Sample Buyer Companies and Websites
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| Current-year attendee / speaker organization list not publicly provided in the materials supplied | N/A | A reliable buyer-company table cannot be populated with confirmed organizations without an official 2026 attendee, speaker, sponsor, or exhibitor list. | N/A | N/A | Confirmed gap in public data |
| Organizer-published buyer-side company data | N/A | Not supplied for this research request; buyer validation should rely on official participant directories once released. | N/A | N/A | Confirmed gap in public data |
| Prior-year participation evidence | Historical reference only | The user-provided event description identifies attendee groups, but no named organizations were included. | N/A | Medical Oncologist; Director Clinical Research; Head of Oncology; Trial Operations Lead; Medical Affairs Director | Historical / prior-year evidence |
Suitable for B2B attendee list building only after official participant evidence is released. At present, this event is better treated as a targeted oncology decision-maker environment than as a fully verifiable current-year attendee-list source.
5. Job Profiles, Industries and Event Type
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | Head of Oncology | Clinical / Medical | Director / Executive | Core clinical decision-maker for cancer care programs, treatment pathways, and innovation adoption. |
| 2 | Medical Oncologist | Clinical / Medical | Manager / Director / Individual Contributor | High influence on adoption of therapeutics, diagnostics, digital tools, and patient management pathways. |
| 3 | Director of Clinical Research | Research / Clinical Trials | Director | Key buyer/influencer for trial systems, CRO support, data capture, and translational platforms. |
| 4 | Principal Investigator | Research | Senior Individual Contributor / Director | Shapes scientific collaborations, trial participation, and study technology selection. |
| 5 | Clinical Trial Manager | Clinical Operations | Manager | Strong operational buyer influence over trial execution tools and support vendors. |
| 6 | Medical Affairs Director | Medical Affairs | Director | Important for scientific partnership, education, speaker engagement, and research collaborations. |
| 7 | Procurement Manager | Procurement / Supply Chain | Manager | Relevant for hospital systems, lab consumables, devices, and oncology department procurement. |
| 8 | Head of Translational Medicine | R&D / Translational Science | Director / VP | High-value target for biomarker platforms, omics solutions, and lab-to-clinic data integration. |
| 9 | Hospital Director / Service Line Director | Operations / Administration | Director / Executive | Influences institutional budgets, oncology service growth, and strategic partnerships. |
| 10 | Business Development Director | Business Development / Partnerships | Director | Important for licensing, strategic alliances, and collaboration-led outreach. |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Hospital & Health Care | Core clinical delivery organizations for oncology treatment and care pathways | Hospital oncology service lines, procurement, digital care, and operational solutions |
| 2 | Pharmaceuticals | Oncology drugs, medical affairs, trial sponsorship, and scientific collaboration | Clinical partnerships, evidence generation, medical communications, and services |
| 3 | Biotechnology | Strong fit for translational research, precision oncology, biomarkers, and innovation | R&D partnerships, assay tools, platforms, and innovation sourcing |
| 4 | Research | Academic and non-commercial cancer research institutions are central attendee profiles | Scientific collaboration, lab platforms, data systems, grant-backed procurement |
| 5 | Medical Devices | Relevant for diagnostic devices, oncology treatment support, imaging, and monitoring | Clinical evaluation, procurement, and specialist department sales |
| 6 | Information Technology & Services | Supports digital health, trial management, oncology data, AI, and integration needs | Clinical software, analytics, interoperability, workflow, and patient engagement tools |
| 7 | Higher Education | Medical universities and academic centers contribute research leadership and trial capacity | Research collaborations, equipment, publications, and academic partnerships |
| 8 | Government Administration | Public health systems and national or regional health bodies can influence screening and care priorities | Policy engagement, public programs, institutional partnerships |
| 9 | Health, Wellness & Fitness | Relevant for survivorship, supportive care, rehabilitation, and prevention-related solutions | Adjacency targeting for patient support and care-continuity offerings |
| 10 | Management Consulting | Healthcare strategy, trial optimization, reimbursement, and transformation advisors often work in this ecosystem | Partnerships, subcontracting, and channel relationships |
6. Estimated Attendance
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | Attendance figure not publicly confirmed by the organizer | Unconfirmed | No current-year organizer data supplied | Do not use current-year volume claims in outreach without official confirmation. |
| Historical attendance | 2,500+ global participants | Historical / prior-year evidence | User-provided 2025 reference description | Not a confirmed attendance figure for the 2026 Barcelona edition. |
| Exhibitor count | Not publicly confirmed | Unconfirmed | No exhibitor prospectus or exhibitor list supplied | Medical congresses often emphasize delegates and speakers over large expo floors. |
| Buyer count | Not publicly confirmed | Unconfirmed | No buyer registration segmentation supplied | Buyer influence is likely concentrated among clinicians, researchers, and hospital stakeholders rather than formal hosted buyers. |
| Speaker count | Not publicly confirmed | Unconfirmed | No agenda or speaker directory supplied | Speaker organizations would materially improve account-targeting once released. |
| Sponsor count | Not publicly confirmed | Unconfirmed | No sponsor list supplied | Sponsor data would help identify vendor ecosystems and partnership channels. |
7. Key Focus Areas and Buyer Engagement
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Precision oncology | Biomarker identification, treatment matching, molecular decision support | Research collaborations, pilot studies, technology demos | Genomics, biomarkers, AI decision support, diagnostic platforms |
| Immuno-oncology | Evidence generation, clinical validation, patient stratification | Scientific exchange with pharma, biotech, and investigator groups | Assays, trial support, translational services, companion diagnostics |
| Clinical trials | Faster study execution, site coordination, patient recruitment, data quality | Trial operations outreach, sponsor-site meetings, vendor evaluation | CRO, eClinical, eConsent, patient recruitment, sample logistics |
| Radiology and imaging advancements | Improved detection, staging, response monitoring, workflow efficiency | Clinical evaluation and specialist department discussions | Imaging software, decision support, advanced diagnostic systems |
| Patient-centered care | Workflow, adherence, patient engagement, survivorship support | Hospital operations and care-model discussions | Patient communication, monitoring, care coordination, supportive care tools |
| Translational research | Move discoveries from lab to clinic more efficiently | Academic-biotech-pharma partnering | Lab platforms, data integration, biobanking, analytical services |
| Healthcare innovation | Digital transformation, efficiency, evidence, interoperability | Innovation showcase and strategic partnership discussions | Health IT, analytics, AI, integration services, workflow optimization |
Lead Quality Assessment
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | High | The event appears highly relevant for specialized oncology decision-makers and influencers, especially in clinical and research settings. |
| Decision-maker availability | High | Scientific congresses often attract senior clinicians, investigators, and medical leadership, though direct procurement volume may be narrower than trade expos. |
| Data collection potential | Medium | Current public participant data is limited in the materials provided. Lead quality improves significantly if official speaker, sponsor, or attendee directories become available. |
| Apollo targeting potential | Very High | The oncology market maps well to Apollo filters across hospitals, pharma, biotech, research institutions, and health IT vendors. |
| Geographic targeting potential | High | Barcelona, Spain, and wider Europe provide strong segmentation options for localized or pan-European campaigns. |
| Best outreach approach | High | Use disease-area relevance, research collaboration value, workflow improvement, and evidence-based positioning rather than generic sales messaging. |
| Overall lead quality | High | Strong for specialized B2B medical and life sciences offerings; less suitable for broad-based mass-market list selling until current-year participant proof is available. |
| Best use case | High-value ABM and account targeting | Best suited for precision outreach to oncology stakeholders, clinical research accounts, and life sciences partnerships. |
| Limitations / risks | Medium | Current-year public data gaps limit validated attendee-list construction and confirmed organization-level attendance claims. |
Apollo.io Targeting Recommendation
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Hospital & Health Care; Pharmaceuticals; Biotechnology; Research; Medical Devices; Information Technology & Services; Higher Education; Government Administration | Align search with likely oncology ecosystem participants and institutional buyers. |
| Departments | Medical; Clinical Research; R&D; Procurement; Operations; Information Technology; Business Development; Partnerships; Innovation | Narrow outreach to functions with clinical, research, or purchasing influence. |
| Seniority | Director; VP; C-Level; Head; Manager; Partner; Senior | Capture both strategic decision-makers and operational implementers. |
| Job titles | Head of Oncology; Medical Oncologist; Director Clinical Research; Principal Investigator; Clinical Trial Manager; Medical Affairs Director; Head of Translational Medicine; Procurement Manager; Oncology Service Line Director; Business Development Director | Focus on roles most likely to influence oncology solutions, trials, partnerships, and hospital adoption. |
| Geography | Spain; Catalonia; Barcelona; United Kingdom; Germany; France; Italy; Netherlands; Switzerland; Belgium; Nordics; broader Europe | Reflect likely event attendance corridors and pan-European oncology relevance. |
| Employee size | 51-200; 201-500; 501-1,000; 1,001-5,000; 5,001-10,000; 10,001+ | Cover both specialist biotech firms and major hospital/pharma institutions. |
| Keywords | oncology, cancer research, immuno-oncology, clinical trials, precision medicine, translational medicine, biomarker, radiology, patient care, cancer center | Improve title and account relevance for disease-specific outreach. |
| Technologies, if relevant | Clinical trial software; EHR/EMR; genomics; imaging analytics; lab information systems; AI in healthcare | Useful when the client sells interoperable digital or scientific platforms. |
| Revenue range, if relevant | Mid-market to enterprise for pharma and health systems; emerging-growth for biotech | Supports segmentation by budget maturity and sales cycle complexity. |
| Company type | Hospitals; academic medical centers; pharmaceutical companies; biotech firms; cancer research institutes; public health bodies | Aligns with the most probable event participant categories. |
Suggested Apollo Search Logic: (“oncology” OR “cancer research” OR “immuno-oncology” OR “precision medicine” OR “translational medicine” OR “clinical trials”) AND (hospital OR pharma OR biotech OR research institute) AND (Director OR Head OR VP OR Manager OR Principal Investigator OR Medical Affairs).
Client Fit Review Required
Please share the client website or product/service details. I will review the client offering and identify the highest-fit buyer companies, Apollo industries, seniority levels, departments, and job titles from this event.
Sources & Verification Notes
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| User-provided event details | Client-supplied event data | Event title, city, country, venue field, and 2026 event dates | Medium |
| User-provided reference description | Historical / descriptive reference | Prior reference positioning, attendee profile, thematic focus, and historical attendance statement of 2,500+ for the 2025 edition | Medium; not current-year organizer confirmation |
| Current-year official organizer / venue / attendee directory links | Primary-source gap | Organizer, official website, current-year attendance, speaker list, sponsor list, and buyer organization details were not supplied and therefore remain unverified in this report. | High confidence in stating unverified status |
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to 6th European Congress on Cancer and Oncology Research — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds